Form 4: Verastem Director Michelle Robertson Receives Significant Equity Grants

Verastem, Inc. Director Michelle Robertson was granted 8,333 Restricted Stock Units (RSUs) and options to purchase 12,500 shares of common stock, aligning her compensation with long-term company performance.

Summary

• Michelle Robertson, a Director of Verastem, Inc. (VSTM), acquired 8,333 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 22, 2025, with a price of $0.00 per share.
• Following this transaction, Ms. Robertson beneficially owns a total of 16,666 shares of Common Stock.
• The RSUs are granted under the Issuer's Amended and Restated 2021 Equity Incentive Plan and will vest in twelve equal installments.
• The first eleven RSU installments will vest monthly from June 2025 to April 2026, with the final installment vesting on the earlier of the day before the 2026 Annual Meeting of Stockholders or May 31, 2026, contingent on continued service as a director.
• Additionally, Ms. Robertson acquired stock options to purchase 12,500 shares of Common Stock on May 22, 2025, with an exercise price of $7.48 per share and an expiration date of May 22, 2035.
• These stock options also vest in twelve equal installments, with the first eleven vesting monthly from June 2025 to April 2026, and the final installment vesting on the earlier of the day before the 2026 Annual Meeting of Stockholders or May 31, 2026, contingent on continued service as a director.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is a positive for aligning management interests with shareholders. It does not contain any negative or unexpected information.

Positives

• The grant of RSUs and stock options aligns the director's interests with long-term shareholder value creation, as vesting is contingent on continued service and potential stock price appreciation.
• Equity compensation is a standard practice for attracting and retaining qualified board members, indicating a commitment to strong corporate governance.

Future Outlook

The future outlook for the reporting person's equity holdings is tied to her continued service as a director through May 2026, allowing for the full vesting of the granted RSUs and stock options. The stock options have a long-term expiration date of May 2035, providing a significant window for potential exercise.

Management Comments

• The grants were made under the Issuer's Amended and Restated 2021 Equity Incentive Plan, indicating a structured approach to executive and director compensation.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across publicly traded companies, particularly in the biotechnology sector, to align leadership incentives with long-term company performance and shareholder interests. Such grants are a standard component of director remuneration packages.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as a form of director compensation is a widely adopted practice across industries, including biotechnology, aligning with global benchmarks for corporate governance and incentive structures.
• The vesting schedule over approximately one year is typical for annual director grants, ensuring continued commitment and service.
• The exercise price of $7.48 for the stock options is likely the closing price of Verastem (VSTM) common stock on the grant date, which is standard for 'at-the-money' option grants.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's stock performance, potentially leading to more focused decision-making aimed at increasing shareholder value.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• Michelle Robertson's continued service as a director of Verastem, Inc. is required for the vesting of the granted RSUs and stock options.
• The company will continue to report any changes in beneficial ownership for its insiders via subsequent Form 4 filings.

Key Dates

Keywords

Verastem, VSTM, SEC Form 4, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Insider Transaction, Director Compensation, Corporate Governance